Home » Expert Content » Biologics Development » What are the latest developments for SMARTag ADC technology?

What are the latest developments for SMARTag ADC technology?

Summary: Antibody drug conjugates (ADCs) combine the targeted binding specificity and half-life benefits of monoclonal antibodies with the potency advantages of small molecule chemotherapy or therapeutic agents. With a large and growing list of products in clinical and pre-clinical development, ADCs are emerging as one of the fastest growing development areas in biologic anti-cancer treatment.